Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Accumulated Expenses: 2012-2024

Historic Other Accumulated Expenses for Heron Therapeutics (HRTX) over the last 10 years, with Dec 2024 value amounting to $41.8 million.

  • Heron Therapeutics' Other Accumulated Expenses rose 19.11% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 19.11%. This contributed to the annual value of $41.8 million for FY2024, which is 0.24% down from last year.
  • As of FY2024, Heron Therapeutics' Other Accumulated Expenses stood at $41.8 million, which was down 0.24% from $41.9 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Other Accumulated Expenses peaked at $41.9 million during FY2023, and registered a low of $25.9 million during FY2021.
  • In the last 3 years, Heron Therapeutics' Other Accumulated Expenses had a median value of $41.8 million in 2024 and averaged $40.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first declined by 22.35% in 2020, then surged by 49.09% in 2022.
  • Yearly analysis of 5 years shows Heron Therapeutics' Other Accumulated Expenses stood at $28.4 million in 2020, then dropped by 8.85% to $25.9 million in 2021, then surged by 49.09% to $38.6 million in 2022, then increased by 8.57% to $41.9 million in 2023, then decreased by 0.24% to $41.8 million in 2024.